These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8359189)

  • 1. The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects.
    Shiga T; Fujimura A; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1993; 44(5):489-92. PubMed ID: 8359189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.
    Shiga T; Fujimura A; Tateishi T; Ohashi K; Ebihara A
    J Clin Pharmacol; 1993 Aug; 33(8):756-61. PubMed ID: 8408738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects.
    Fujimura A; Kumagai Y; Sugimoto K; Nakashima H; Kajiyama H; Ebihara A; Ohashi K
    Eur J Clin Pharmacol; 1990; 38(2):133-7. PubMed ID: 2338109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.
    Langner B; Lemmer B
    Eur J Clin Pharmacol; 1988; 33(6):619-24. PubMed ID: 3366165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects.
    Khodadoustan S; Nasri Ashrafi I; Vanaja Satheesh K; Kumar C; Hs S; S C
    Clin Exp Hypertens; 2017; 39(6):520-526. PubMed ID: 28598202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady state relative bioavailability and pharmacokinetics of oral propranolol in black and white North Americans.
    Sharoky M; Perkal M; Turner R; Lesko LJ
    Biopharm Drug Dispos; 1988; 9(5):447-56. PubMed ID: 3224162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.
    Wong L; Nation RL; Chiou WL; Mehta PK
    Br J Clin Pharmacol; 1979 Aug; 8(2):163-7. PubMed ID: 486291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation.
    Sica D; Frishman WH; Manowitz N
    Heart Dis; 2003; 5(3):176-81. PubMed ID: 12783630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability.
    Mansur AP; Avakian SD; Paula RS; Donzella H; Santos SR; Ramires JA
    Braz J Med Biol Res; 1998 May; 31(5):691-6. PubMed ID: 9698776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of morning or evening administration on absorption of theophylline.
    Su YM; Cheng TP; Yeh TW; Wen CY; Wang DI
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):113-8. PubMed ID: 10677921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid, and p-hydroxypropranolol in human plasma and urine.
    Garceau Y; Davis I; Hasegawa J
    J Pharm Sci; 1978 Jun; 67(6):826-31. PubMed ID: 660467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between propranolol and propafenone in healthy volunteers.
    Kowey PR; Kirsten EB; Fu CH; Mason WD
    J Clin Pharmacol; 1989 Jun; 29(6):512-7. PubMed ID: 2754020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
    Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic interaction study of avitriptan and propranolol.
    Marathe PH; Greene DS; Kollia GD; Barbhaiya RH
    Clin Pharmacol Ther; 1998 Mar; 63(3):367-78. PubMed ID: 9542480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of aging on the oxidative and conjugative metabolism of propranolol.
    Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A
    Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is diurnal variation in absorption of slow-release aminophylline an age-related phenomenon?
    Rodgers A; Bateman DN; Woodhouse KW
    Eur J Clin Pharmacol; 1988; 33(6):593-7. PubMed ID: 3366162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian changes of valproate kinetics depending on meal condition in humans.
    Ohdo S; Nakano S; Ogawa N
    J Clin Pharmacol; 1992 Sep; 32(9):822-6. PubMed ID: 1430301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of naphthoxylactic and naphtoxyacetic acid in human plasma following propranolol administration.
    Pritchard F; Schneck D; Hayes A
    Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):279-86. PubMed ID: 461953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.